Affinity proteomics-based non-invasive detection of clinically significant liver disease
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Since liver disease is often clinically unapparent, non-invasive biomarkers predicting future major adverse liver outcomes (MALO) are urgently needed. Therefore, we assessed the usefulness of a novel, proximity extension assay (PEA)-based high-throughput targeted proteomics method to predict MALOs.
Methods
PEA plasma proteomic data (>2900 proteins) and clinical information were accessed from the population-based UK Biobank (UKB) cohort, including >53000 individuals with a median follow-up of >10 years and its subcohorts of obese (>12900) and diabetic (>1600) participants. The validation cohorts comprised 287 subjects with severe alpha1-antitrypsin deficiency (AATD), Pi*ZZ genotype, and 960 people living with HIV (PLHIV), who underwent liver stiffness measurement (LSM) via transient elastography. Selected PEA parameters were compared to routine measurements. Bayes-moderated linear models (age and sex as covariates) assessed the differential abundance. Logistic regression was used to identify and validate a novel prognostic score.
Results
Routine gamma-glutamyltransferase (GGT) and aspartate aminotransferase (AST) levels strongly correlated with PEA-based measurements (r=0.91 and r=0.68, respectively). Similarly, PEA-based thrombospondin-2 levels strongly correlated with immunoassay-based values (r=0.85). Twenty proteins were consistently associated with future MALOs/increased LSM in all cohorts. UKB cohort was used to develop a novel five-component PEA score that demonstrated superior predictive power (AUROC=0.84) compared to established indices/scores, including AST-to-platelet-ratio index (APRI, AUROC=0.73) and Fibrosis-4 index (FIB4, AUROC=0.72) and its attractive predictive power was sustained in diabetic/obese subcohorts. In PLHIV and AATD validation cohorts, all five components showed gradual increases across fibrosis stages, and PEA score numerically outperformed APRI/FIB4 in predicting significant liver disease.
Conclusion
Our study identifies a new PEA score consisting of epithelial/hepatic stellate cell markers that demonstrates an attractive discriminative ability in several independent cohorts and different liver disease aetiologies.
